Gene Therapies Will Be A Bigger Cost Issue In 2021, PwC Predicts
Executive Summary
The expected launch of BioMarin's Roctavian for hemophilia A is expected to heighten the profile of expensive gene therapies on payers' radar. Specialty drug costs are expected to continue to grow in 2021.
You may also be interested in...
Not Such A Sure Thing: FDA Knocks Back BioMarin’s Roctavian
BioMarin’s confidence that its first-ever hemophilia gene therapy would be cleared by the US FDA was shaken by a complete response letter that the company claims changed the requirements for approval.
Not Such A Sure Thing: FDA Knocks Back BioMarin’s Roctavian
BioMarin’s confidence that its first-ever hemophilia gene therapy would be cleared by the US FDA was shaken by a complete response letter that the company claims changed the requirements for approval.
BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.